Adenosine A 1 receptor protein levels and activity is increased in the cerebral cortex in Creutzfeldt-Jakob disease and in bovine spongiform encephalopathy-infected bovine-PrP mice

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 10, 2006, Pages 964-975

  Rodríguez, Agustín ^a   Martín, Mairena ^c   Albasanz, José Luís ^c   Barrachina, Marta ^a   Espinosa, Juan Carlos ^d   Torres, Juan María ^d   Ferrer, Isidro ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^d Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

Author keywords

Adenosine receptor; Bovine spongiform encephalopathy; Bovine PrP transgenic mice; Creutzfeldt Jakob disease; Prion

Indexed keywords

6 N CYCLOPENTYLADENOSINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENYLATE CYCLASE; CYCLIC AMP; CYCLOHEXYLADENOSINE; FORSKOLIN; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; MESSENGER RNA; METABOTROPIC RECEPTOR; PHOSPHOLIPASE C; PRION PROTEIN; PROTEASE RESISTANT PRION PROTEIN; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOVINE SPONGIFORM ENCEPHALOPATHY; BRAIN CORTEX; BRAIN MEMBRANE; BRAIN METABOLISM; BRAIN SPONGIOSIS; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE COURSE; ENZYME INHIBITION; FEMALE; FRONTAL CORTEX; GLIOSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; RECEPTOR UPREGULATION; SCRAPIE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; AGED; ANIMAL; CATTLE; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; WESTERN BLOTTING;

ADENYLATE CYCLASE; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; CATTLE; CEREBRAL CORTEX; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MIDDLE AGED; PRPC PROTEINS; RECEPTOR, ADENOSINE A1; RECEPTORS, ADENOSINE A2; RNA, MESSENGER;

EID: 33749493534     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000235120.59935.f5     Document Type: Article

References (59)

1. Prusiner SB. The prion diseases of humans and animals. In: Rosenber RN, Prusiner SB, Di Mauro S, Barchi RL, eds. The Molecular and Genetic Basis of Neurological Diseases. Boston: Butterworth-Heinemann, 1997:165-86
2. Collinge J. Prion diseases of human and animals: Their causes and molecular basis. Annu Rev Neurosci 2001;24:519-50
3. Aguzzi A, Montrasio F, Kaeser PS. Prions: Health scare and biological challenge. Nat Rev Mol Cell Biol 2001;2:118-26
4. Bratosiewicz-Wasik J, Wasik TJ, Liberski PP. Molecular approaches to mechanisms of prion diseases. Folia Neuropathol 2004;42:S33-46
5. Budka H, Head MW, Ironside JW, et al. Sporadic Creutzfeldt-Jakob disease. In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003:287-97
6. De Armond SJ, Kretzschmar HA, Prusiner SB. Prion diseases. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology, vol II. London: Arnold, 2003:273-323
7. Knight RSG, Will RG. Prion diseases. J Neurol Neurosurg Psychiatry 2004;75:S136-42
8. Sakudo A, Lee D, Yoshimura E, et al. Prion protein suppress perturbation of cellular copper homeostasis under oxidative conditions. Biochem Biophys Res Commun 2004;313:850-55
9. Brown DR, Herms JW, Schmidt B, et al. PrP and beta-amyloid fragments activate different neurotoxic mechanisms in cultured mouse cells. Eur J Neurosci 1997;9:1162-69
10. Ferrer I, Puig B. GluR2/3, NMDA1 and GABAA receptors in Creutzfeldt-Jakob disease. Acta Neuropathol 2003;106:311-18
11. Rodríguez A, Freixes M, Dalfó E, et al. Metabotropic glutamate receptor/phospholipase C pathway: A vulnerable target to Creutzfeldt-Jakob disease in the cerebral cortex. Neuroscience 2005;131:825-32
12. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998;50:413-92
13. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55
14. Wittendorp MC, Von Frijtag Drabbe Künzel J, Ijzerman AP, et al. The mouse brain adenosine A1 receptor: Functional expression and pharmacology. Eur J Pharmacol 2004;487:73-79
15. Fredholm BB, Ijzerman AP, Jacobson KA, et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52
16. Yaar R, Jones MR, Chen J-F, et al. Animal models for the study of adenosine receptor function. J Cell Physiol 2005;202:9-20
17. Reppert SM, Weaver DR, Stehle JH, et al. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol 1991;5:1037-48
18. Dixon AK, Gubitz AK, Sirinathsinghji DJ, et al. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996;118: 461-68
19. Wardas J. Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 2002;54:313-16
20. Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988;9:130-34
21. Arrigoni E, Rainnie DG, McCarley RW, et al. Adenosine-mediated presynaptic modulation of glutamatergic transmission in the laterodorsal tegmentum. J Neurosci 2001;21:1076-85
22. Dunwiddie TV, Hoffer BJ. Adenine nucleotides and synaptic transmission in the in vitro rat hippocampus. Br J Pharmacol 1980;69:59-68
23. Kocsis JD, Eng DL, Bjhisitkul RB. Adenosine selectively blocks parallel-fiber-mediated synaptic potentials in rat cerebellar cortex. Proc Natl Acad Sci U S A 1984;81:6531-34
24. Ciruela F, Escriche M, Burgueno J, et al. Metabotropic glutamate 1a and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem 2001;276:18345-51
25. Schubert P, Ogata T, Ferroni S, et al. Protective mechanisms of adenosine in neurons and glials cells. Ann NY Acad Sci 1997;825:1-10
26. Zalewska-Kaszubska J. Neuroprotective mechanisms of adenosine action in CNS neurons. Neurol Neurochir Pol 2002;36:329-36
27. Hartwick AT, Lalonde MR, Barnes S, et al. Adenosine A1-receptor modulation of glutamate-induced calcium influx in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004;45:3740-48
28. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-33
29. Braak H, Braak E. Temporal sequence of Alzheimer's disease related pathology. In: Peters A, Morrison JH, eds. Cerebral Cortex, vol. 14, Neurodegenerative and Age-Related Changes in Structure and Function of Cerebral Cortex. New York, Boston, Dordrecht, London, Moscow: Kluwer Academic/Plenum Publishers, 1999:475-512
30. Castilla J, Gutierrez-Adan A, Brun A, et al. Early detection of PrP(res) in BSE-infected bovine PrP transgenic mice. Arch Virol 2003;148:677-91
31. Scott MD, Groth D, Foster D, et al. Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 1993;73:979-88
32. Scott M, Foster D, Mirenda C, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 1989;59:847-57
33. Barrachina M, Castano E, Ferrer I. TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int 2006;49:276-84
34. Ruiz MA, Albasanz JL, León D, et al. Different modulation of inhibitory and stimulatory pathways mediated by adenosine after chronic in vivo agonist exposure. Brain Res 2005;1031:211-21
35. Ruíz A, Sanz JM, Gonzalez-Calero G, et al. Desensitization and internalization of adenosine A1 receptors in rat brain by in vivo treatment with R-PIA: Involvement of coated vesicles. Biochim Biophys Acta 1996;1310:168-74
36. Angulo E, Casadó V, Mallol J, et al. A1 Adenosine receptors accumulate in neurodegenerative structures in AD and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol 2003;13:440-51
37. Adori C, Kovaks GG, Low P, et al. The ubiquitin-proteasome system in Creutzfeldt-Jakob and Alzheimer disease: Intracellular redistribution of components correlates with neuronal vulnerability. Neurobiol Dis 2005;19:427-35
38. Sun H-X, Young HW, Molina JG, et al. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 2005;115:35-43
39. Johnston JB, Silva C, Gonzalez G, et al. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 2001;49:650-58
40. Tsutsui S, Schermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004;24:1521-29
41. Lasley RD, Narayan P, Uittenbogaard A, et al. Activated cardiac adenosine A(1) receptors translocate out of caveolae. J Biol Chem 2000;275:4417-21
42. Escriche M, Burgueno J, Ciruela F, et al. Ligand-induced caveolaemediated internalization of A1 adenosine receptors: Morphological evidence of endosomal sorting and receptor recycling. Exp Cell Res 2003;285:72-90
43. Taylor DR, Hooper M. The prion protein and lipid rafts. Mol Membr Biol 2006;23:89-99
44. Rudolphi KA, Shubert P. Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia. Behav Brain Res 1997;83:123-28
45. Deckert J, Abel F, Künig G, et al. Loss of human hippocampal adenosine A1 receptors in dementia: Evidence for lack of specificity. Neurosci Lett 1998;244:1-4
46. Schnecko A, Witte K, Bohl J, et al. Adenylyl cyclase activity in Alzheimer's disease brain: Stimulatory and inhibitory signal transduction pathways are differentially affected. Brain Res 1994;644:291-96
47. Yamamoto M, Gotz ME, Ozawa H, et al. Hippocampal level of neural specific adenylyl cyclase type I is decreased in Alzheimer's disease. Biochem Biophys Acta 2000;1535:60-68
48. Caughey B, Landsbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003;26:267-98
49. Matherne GP, Linden J, Byford AM, et al. Transgenic A1 adenosine receptor over-expression increases myocardial resistance to ischemia. Proc Natl Acad Sci USA 1997;94:6541-46
50. Gauthier NS, Headrick JP, Matherne GP. Myocardial function in the working mouse heart overexpressing cardiac A1 adenosine receptors. J Mol Cell Cardiol 1998;30:187-93
51. Yang Z, Sei Y, Cerniway RJ, et al. Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction. Am J Physiol Heart Circ Physiol 2002;282:H949-55
52. Johansson B, Halldner L, Dunwiddie TV, et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci U S A 2001;98:9407-12
53. Dunwiddie TV, Masino SA, Poelchen W, et al. Altered electrophysiological sensitivity to A1 but not to GABAB agonists in the hippocampal CA1 region in A1 receptor knockout mice. Soc Neurosci 2000;26:816-18
54. Fredholm BB. Adenosine and neuroprotection. Int Rev Neurobiol 1997;40:259-80
55. Fowler JC. Adenosine antagonists delay hypoxia-induced depression of neuronal activity in hippocampal brain slice. Brain Res 1989;490:378-84
56. Fowler JC. Adenosine antagonists alter the synaptic response to in vitro ischemia in the rat hippocampus. Brain Res 1990;509:331-34
57. Fredholm BB, Chen JF, Masino SA, et al. Actions of adenosine at its receptor in the CNS: Insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2004;45:385-412
58. Meyer PT, Elmenhorst D, Bier D, et al. Quantification of cerebral A1 adenosine receptors in human using [18F]CPFPX and PET: An equilibrium approach. Neuroimage 2005;24:1192-204
59. Fukumitsu N, Ishii K, Kimura Y, et al. Adenosine A1 receptor mapping of the human brain by PET with 8-dicyclopylelmethyl-1-11C-methyl-3-propylxanthine. J Nucl Med 2005;46:32-37